Carbapenems And Other Agents That Provide Broad-Spectrum Activity Are Preferred By Surveyed Physicians For The Treatment Of Intra-Abdominal Infections

Arlington Medical Resources (AMR) and Decision Resources find that surveyed physicians will increase prescribing of Wyeth’s Tygacil, Merck’s Invanz and Johnson & Johnson’s Doribax in the next five years for the treatment of intra-abdominal infections because of their potent broad-spectrum activity and efficacy against gram-negative and anaerobic organisms. “Treatment for intra-abdominal infections is largely empiric,” stated Lisa Arias, analyst at Decision Resources.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on June 1st, 2009